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Ultrasound Thrombolys|s  In Acute Myocalxilal 
Infarction: Initial Results 
Ud Resenschein, Aria Roth, Shlomo Lanlado, Samuel Basan, Afie sharer, 
Aron Fdmerman, Hylton L Miller. TeI Aviv Medical Center, Tel Aviv, Israel 
We have previously reported our expedence wtlh ultraso~d anglopfaaty in 
experimental and dinicat settings. These sit.as sug~e~ that ulVasound 
selectively ablates thrombi with a wide margin of safety. The purpose of this 
study is to evaluate, for Ille first time, the clinical fees~lity of percutaneous 
comnan] ultrasound thromb~lysis (ULTH) as the primary repeduslon ther- 
apy in acute myocardial infarction (MI). The uHresouP, d thmmbolysis device 
consists of a solid metal probe with a distal multi-wire flexible segment, cor~ 
nected to a 1,6 mm tip. The device fits into a 1 OF guiding calheter over 0,014" 
guidewtm. Eligible patients had acute anterior MI and TIMI 0-1 flow in the 
LAD, To date, ULTH was attempted in 6 consecutive patients (10ts). In 
first pt. ULTH failed. In the follOwing consecutive 5 pts, following a change in 
the technique, sonfcatton (45 kHz, 18 Watts. 3 m) induced TIMI grade 3 flow, 
MLD of 1.7 :J: 0.9 mm and residual stenosis of 45 ~ 24%. There were no 
dissections, perforations, embolizations or spasm. There were no adverse 
events during ULTH. Adjunct PTCA, employed in all pts, resulted in final MLD 
of 2.3 :J: 0.3 mm and residual atenosis of 12 :~ Ib'%. Repeat ang~ at 
10 rain and 24 hr revealed TIMI 3 flow in all pis. In.hospital, 1 Pt. developed 
acute closure on day 5 that was lmated successfully by PTCA. There were no 
deaths, bleeding or need for vascular repair. Conclusion: ULTH is potentially 
a safe and effective device solution for reperfusion therapy in the setting of ML 
~ lntracoronary Adenosine as an Adjunct to 
Combined Use of Primary Angioplacty in Acute 
Myocardial Infarction: Beneficial Eltects on 
Anglographically Assessed No-Reflow 
Made Merzilli, Peele M,~rracotni, End Gliozheni, Enrico Omini, 
Eugenio Pioa.o. CNR, Institute of Clinfcal Physiology. Plea, Italy 
A sound theoretical nd experimental framework exists to support he investi- 
gation of adenosine as an adjunct o reper~uslon therapy among humans with 
acute myocardial infarction. Aim of this pilot study was to evaluate the safety 
and feasibility of Inttacomnmy adenosine (ADO) dudng primary angiopissty, 
as well as its effects on anglographlually assessed "no-reffow" phenomenon, 
Of 40 pts with acute myocerdfal infarction cons~ mfan'ed for primary 
angioplasty0 20 (Group I) received intracoronsry ADO (4 mg over 4 minutes) 
and 20 intr~comnary saline (Group II). The 2 groups were similar for age (I 
= 61 :E 12 vs II ,= 65 :t: 10, p = ns), sex (females: I = 5/20 vs II = 2/10, p 
== ns), location of Infarct-related arteP/(left anterior descending I = 10/20 vs 
II = 12/20, p = ns), time from onset of chest pain to first dilatatton (I = 95 
:1= 59 vs tl 129d: 122 rain, p = ns). No pts hod,amrsantng of chest patn or 
hemodynamic instability or any other limiting side effects during either ADO 
or saline infusion. Following angk~faaty the 2 Groupa had a comperabh~ final 
residual stenosis (% diameter eduction I = 27.4- 11 vs II = 30:4: 12, p = ns), 
but TIMI grade (from 0 = no flow to 3 = norolal flow) in the infarot-mlatad 
artery was 2.7 4. 0.4 in Group I and 2,18 :E 1,25 in Group II (p < 0.01). 
Anglographlcally assessed no-inflow in the infar~t-m~ated artery was present 
in 0 out of 20 pis of Group I and in 6 out of 20 pts of Group II (0 vs 30%, 
p < 0.01). In patients with acute myocardial infarction intracomna~ ADO 
before pflmanj angioplasty is feasible and well tolerated, and is associated 
tO a lower incidence of angtographioally assessed no-fellow in the dilated 
infarct-related artery. 
~ T h e  Effects of Tissue Factor Pathway Inhibitor on 
Myocardial infarct Size 
Basem Koudsl, Edward W. Ferguson, Chester O. Yu, Gary A. Miller, Kurt 
D. Merkel, Tze-Chein Wun, Samuel R. Money, Bruce A, Kraemer. 
Washington University, St. Louis, MO 
Evidence is presented that a novel anticoagulant, Tissue Factor Pathway 
Inhibitor (TFPI), signlflcant~ reduces infarct size in a rabbit myocerdiom 
ischemia/mpeffusion (I/R) model. Recombinant TFPI was examined to de- 
termine its abitfly to enhance survival of jeopam'ized myoca,-dium following 
ischemic insult and repertuslon. Male and female New Zealand White Rab- 
bits were anesthetized, their circumflex artery was OCcluded for a period of 
45 minutes followed by a 3 hour mpeduslon period. In addition to a con- 
trol group (n = 11), two groups motived 10 cc of either TFPI (N = 11.200 
pg/ml) or vehicle (n = 10) infused over 10 seconds into the left atrium (I.A) 
at the onsof of mPedusien. Area at dsk (AAR) was dofen-nined by infusing 
Evans blue into the La, with the circumflex occluded; percentage of AAR 
eurviving was Idantified using oross sscl~ons of lhe left ventdcfe atalned with 
2,3,5-Triphenyl-tebazolium Chloride (TTC) and planimeby measurements, 
Area of necrosis (AN) eq0.~=d aS a percentage of AAR (AN/AAR) showed 
significant ddferances between the TFPI treated animals vs. those l t~ re* 
coived either vehicle or no drug (23.5% vs. 42.5% and 39.1%) respectively, 
p = 0.0006 and o.003). No sign,'¢ant d~erance was observed between the 
groupe with regard to AAR, total LV area or h '~-¢e  of d y s ~  These 
results demonstrate that in the rabbit model, TFPI is an effective agent in 
n~Jcing ~ myocardial in~rct size following isohemia mperfeslon in vivo 
and may prove to be a valuable addition to curmet treatments for acute 
myocerd~ iofa~clion. 
~ R i s k  Factors for Isehemic Stroke in Patients W'dh 
Acute Myocardial Infarction Treated With 
Thrombolyt ic Therapy 
Kenneth W. Mahaffey, Christopher B. Granger, Harvey D. White, Joel 
M. Gore, W. Douglas Weaver, Michael A. Sloan, Eric J. Topoi, Robert 
M. Califf, for the GUSTO Investigators. Duke Universe, Durham, NC 
To determine the factors assudated with ischemlo stroke in patients with 
asute rnyocerdiat infarction (AMI) tmatod with th ren~ therapy, we ana- 
lyzed the 247 (0.6%) patients with bland ischemio atmke in the GUSTO.I b'iat. 
Mortality was 17% and an ad(Mional 40% had moderate or ~ disablfity. 
VadaUes analyzed th.s far incieded amugmphlcs, dtn~at history and risk 
factors, ~ and trsatment ass@vnsm with the most important 
univariable relationships as follows: 
Palkml characteristic Unlvarleble x 2 Odds Ratio* 
O~er age (per 10 yearn) 86 I.? 
History o! stroke 26 4.3 
Diabetes 24 2.t 
Histo~/of hypertension 24 1,9 
Prior angina 24 2.0 
Higher pulse (per 10 beats) 20 1,2 
Prm'icus AMI 19 2,0 
Wame K~nip da~ (per d.ass) 1;' 0.6 
Cunenlsmo~er 16 0,6 
Prev~us bypa~ m~g~y 10 2.2 
Lower weight (per 10 ko) 8 0.8 
Female sex 5 0.7 
"Nip <0.05. 
Ischemlo stroke is an ~ complication I  ~ with AMI treated 
with thrombolysls, hepadn and aspidn but 57% of patients die or suffer 
disability. Risk facfum kn0wn to be essodated with mortality tn patients with 
AMI are also dsk factors for ischemie stroke, an important outcome to include 
in baseline risk assessmenL 
A CompoMte and Practical View of Standard 
CoagulaUon Monitodng in the Identification of 
Pmlento ct Risk for Meier Hemordmp 
Richard C. Becket, Chdatopher P. Cannon, Yunsheng Me, Thomas Hurley, 
James HeberL Thrombosis Research Center, Untvemily of Massachusetts 
MedP.alSchcot. Wo~r ,  MA 
An ability to identify patients likely to expeflanco major hemorrhage fol- 
lOWing thrombatytlc and ~ anticoagulant therapy is of paramount 
clinical importance. Patients par l~t ing in TIMI 5 (n = 246) received ac- 
ceisrated IPA and either hepedn (target aPTT 65--90 sac) or himdin (fixed 
dose), 
The probability of hemonhage increased 2% for each 1 sac increase in 
aPTT. By multhradable analysis, 12 h aPT'l" was independently associated 
with major hemenhage (p < 0.01), A 12 h aPTT _> 85 sac yielded esnsitivity, 
specificity, positive and negative predceve values of 73%, 53%, 23%° and 
90%. In condush~l, the standard aPTT measurement is a clinically useful 
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tool when the target level of anticoagulation is set below 85 seconds - -  a 
common range in current practice, 
[ '~ -3 - '~  Intense Metabolic Control Decreases Long-Term 
Mortal ity and Morbidity in Diabetics With 
Myocardial  Infarction 
K. Malmberg, L Ryd~n, for t~e Swedish DIGAMI Study Group. Cardiology 
Department, Karolinska Hospital, Stockholm, Sweden 
Diabetic pat with acute myocardial infarction (AMI) has a poor prognosis. 
Recent data indicate that glycemic control predicts cardiovascular morbidity 
and mortality in non insulin dependent. 
Material and methods: We tested insulin-glucose infusion as soon as 
possible after onset of AMI followed by ibng-term multi dose insulin in a 
prospective rendemlsed study (DIGAMI) recruiting 620 diabetic pat with AML 
Half of the pat served as a control group (CG) while the remaining subjects 
constituted an insulin treatred group (IG). Data are from one year of follow 
up. 
Results: One year mortality decreased from 26=/0 in the CG to 19=/o in the 
IG (p < 0.05). The effect was most pronounced in diabetics without previous 
insulin and at low cardiovascular isk (reduction = 52%; < 0.02). The most 
frequent cause of mortality was congestive heart failure (CHF), Cardiovas- 
cular mortality (CHF, fatal rainfamtion, sudden death, stroke) tended to be 
less frequent in the IG. The two groups did differ as regards need for revas- 
cularication or hospital care during the year of follow up. Rainfarction was 53 
(28% fatal) in the IG vs 55 (45% fatal) in CG (NS). In a multivariate analysis 
age, previous CHF, admission blood glucose and previous insulin therapy 
independently predicted one year mortality. Metabolic control at admission 
predicted mortality in CG but not in IG. Concomitant beta blockade was a 
predictor for survival among CG whereas thmmbolysfs was most efficient in 
IG. 
Conclusion: Fatal reinfarction and CHF contribute to the increased mortality 
in diabetic pat with AMI. Intensive metabolic ontrol by means of insulin lowers 
mortality and morbidity. Beta blockade did not exert further benefits in Insulin 
treated pat indicating similar mechanisms of action. 
~ Effect Lisinopri l  on Early Mortality o f  Treatment in 
Patients With Acute Myocardial InfareUon at 
Different Risk Profile: Data From the GISSI-3 Study 
GISSI-3 Investigators. M. I~egri Insfitute and ANMCO, Italy 
GISSI-3, ISIS-4, and CCS-1 trials showed a mortality reduction with an early 
(within 24-36 h) treatment with ACE-inhibitors (ACE-i) of unsaiectad 10ts with 
AML In these trials a significant reduction in mortality was already evident in 
the first 5 days of treatment. In pts enrolled in the GISSI-3 study, we evaluated 
early (0 to 5 days) mortality in lisinopdl (L) and no-lisinopril (no-L) treated pts, 
split by subgroups at different baseline risk. 
0-5 days mortality % L no.L  Reduction Livestsaved 
% x 1000 
Overall (n.19318) 3.3 3,8 -13.1 5 
Killip 1 (n.18035) 2.5 2.9 -13.8 4 
Killip 2 + 3 (n.2738) 8.3 9.5 -12.6 12 
Anterior MI (n.5188) 2.5 3.4 -26.5 9 
Inferior MI (n.6105) 1.1 1.6 -31.2 5 
The trend in early mortality reduction was consistent in all subgroups at 
different risk profile, with a greater absolute benefit in the subgreuns at higher 
risk. Analyzing the time course of the L effect split by Killip class at entry, 
an early benefit from L treatment was observed either in patients in Killip 
class 1 or in those in Killip class 2 or 3. From day 6 to 42, no further benefit 
could be seen in lots in Killip class f, while Killip class 2 or 3 pts showed, 
as expected, a further late mortality reduction (18 lives saved per 1000), 
being these patients similar to those randomized in the AIR; study. These 
findings support an early treatment with ACE-i of relatively unselected pts 
with MI and its continuation for a long period of time only in those with 
post-AMI left ventricular failure and/or dysfunction. Further investigations 
are needed to explain the mechanisms underlying the early benefit, which 
appears different from and complementary to the favourabte modifications of 
ventrlcular emodelling induced by ACE-L 
Effects on Venlr icular Arrhythmlas of  an Early 
Uainopdl  Treatment In Patients With Acute 
Myocardial Infarction: The GISSI-3 Experience 
Aldo P. Maggioni, Fabrlzio Pizzetti, Eugenio Santoro, Roberto Latini, 
Giulio Zuanetti, MarlaGrazia Frenzosi, on behalf of the GISSI.3 
Investigators. ANMCO and M. Negri Institute, Italy 
The activation of renin-angiotensin-aldosterone system after myocardial in- 
farction (MI) can increase frequency and complexity of ventrlcular arrbyth- 
mias (VA) after MI. The effects of a lisinopdl (L) treatmenL started in GISSI-3 
study within 24 h from symptom onset, was evaluated on (a) life-threatening 
VA in the 18895 pts with complete in-hospital data and (b) VA profile in the 
12"327 pts with pre~ischarge 24 h ECG monitoring data available. 
The rate of pts with In-hospital life-threatening VA and with VA at predis- 
charge 24 hour ECG monitoring in the L and no.L groups is reported In the 
table: 
In-Hospital VA Lisinopdl (n.9435) No-Ustnopril (n.9460) 21) 
VF % 2.5 2.7 NS 
sVT % 1.9 2.4 0.03 
VF and/or sv'r % 4.0 4.7 0.01 
24 h ECG VA Lisinopril (n.6165) No-Usinopril (n.6162) 2p 
0 PVC % 39.1 39.0 NS 
1-10 PVCs % 43.1 42.8 NS 
> 10 PVCs/h % 17.8 18.2 NS 
nsVT % 5.2 5.1 NS 
VF = ventficular fibrillation, SVT = sustained ventficular tachicardia, PVC = premature ven- 
tricular contractions, nsVT = non-suslained ventricular laehlcardia. 
While L treatment did not influence the VA profile detected by pre<lischarge 
24 h ECG monitoring, in-hospital life-thraatening VA ware less frequent in pts 
allocated to L, This "antiarrbythmib" effect of L in the early phase of MI could 
have contributed to the reduction of eady mortality shown with this treatment 
in GISSI-3 trial. 
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~ " ~  Analysis of the Occurrence and Clinical 
Significance of  Thrombocytopenla  With c7E3 
(Abciximab) in the EPIC Trial 
scott D. Berkowitz, David C. Sane, Jane H. Shavender, Kristina N. Sigmon. 
Eric J. Topoi, Robert M. Ca,if, for the Evaluation of 7E3 for the Prevention of 
Ischemic Complications (EPIC) Study Group. Duke University; Durham, NC; 
Wake Forest University, Winston-Salem, NC 
To understand the role of thrombocyfopenia (7) in hemorrhagic omplica- 
tions associated with the plataiet GP lib/Ilia inhibitor c7E3 (abciximab), we 
analyzod the data from EPIC, a 2,099 patient randomized trial of placebo (P), 
c7E3 bolus (B), or c7E3 bolus + 12 hr infusion (B +/) during PTCA. Twas 
defined as a platelet decrease to < 100 K/pl. Nadir platslet counts did not 
differ between those receiving c7E3 or P (mean 67.7 vs 68.6). Twas more 
likely to occur in patients who were older (mean 64 vs 60 yr), had peripheral 
vascular disease (15 vs 9%) and 3 vessel coronary disease (26 vs 14%). 
Twas associated with recurrent ischemia, more frequent revascoladzation, 
and increased mortality. A trend toward excess Twas seen in the B + I (5.4%) 
versus the B (3.0=/°) and P (3.3%) groups. Patients receiving c7E3 B+ /more 
frequently developed severe T [< 50 Wpl] (1.6%; B 0.4%, P 0.7%). In a 
logistic regression model, the B + I group had a significant relationship with 
T (p = 0.016), which became more significant after adjustment for CABG, 
repeat PTCA, and IABP insertion (p = 0.014). Those with Thad more groin 
site (68 vs 39°/°) and GU tract (10 vs 4=/o) bleeding and hematemeais (10 vs 
0%), but no intracranial hemorrhages or thromboses. In conclusion, we found 
a small but increased likelihood of developing Tin patients receiving c7E3, 
particularly a + I, Among all patients, c7E3 was associated with reduced 
ischemib complications; however, those who developed Twere at increased 
risk of developing iechemia-associated morbidity and mortality. 
